ClinicalTrials.gg
CompletedNCT04179266Updated Feb 24, 2021

Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache

A Phase 1/2 interventional study of Ketamine in Cluster Headache, sponsored by CCH Pharmaceuticals. Completed at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by CCH Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Cluster Headache with a site in Denmark — none open to participants now, none under way, none of them phase 3. Cluster Headache · Denmark.

Enrollment
13th of 15
23 · median 45
Started
2019
the only one that year
Phase 1/2
2 of 20
none open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
CCH Pharmaceuticals

Among the 20 studies in Cluster Headache with a site in Denmark, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 15th registered.

Cluster Headache

123 studies on the registry are indexed under Cluster Headache; 26 are open to participants now.

Browse Cluster Headache studies →

Open to participants now

None of the 20 studies in Cluster Headache with a site in Denmark is open now. The open studies under Cluster Headache, anywhere →

Who these studies take

Of the 18 Cluster Headache studies recruiting now, 7 (39%) set no upper age limit and 6 (33%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Cluster Headache with a site in Denmark as a file.
02

Study summary

Ketamine has been used clinically IV in a very safe manner by a very small number of clinicians, to treat migraines and CH, and various other rarer pain disorders, including mixed headache and neuropathic pain clinical syndromes. In 5 cases taken from Krusz J.C. headache clinic data in Dallas, Texas US, an intranasal spray of ketamine aqueous solution of 100 µL in one nostril were dosed in treatment of patients with refractory chronic cluster headache as an alternative to IV-treatment (data not published).The net conclusion, at this point, is that intranasal ketamine is a legitimate pharmacologic treatment and is safe and has in one case series proven effective for CH rescue.

The CCH patients will be dosed with an intranasal spray containing 172.5 mg ketamine hydrochloride (150 mg ketamine base) per ml in an aqueous solution. The individual dosing includes 15 mg ketamine in an intranasal sprayed volume of 100 µL given in one nose nostril under supervision of a nurse. The treatment is initiated at T0 under a CH attack when the headache pain exceeds NRS = 6 on an NRS pain scale. The first intranasal dose of 15 mg is given at time 0 and at time intervals of 6 minutes. At 15 minutes after 3 doses (45 mg) it is decided to evaluate whether the patient is sufficiently pain relieved (e.g. NRS \< 4) or wants to receive rescue medications instead or if pain is not sufficiently relieved wants to continue until 5 dosing's (75 mg) are received at timepoints T24. The final evaluation of the treatment is performed at T30. Participants are followed up after 1-2 weeks by telehone

03

Conditions studied

  • Cluster Headache

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age between 18 and 60 years
  • Diagnose: Chronic cluster headache according to ICHD-3 criteria (1)
  • Body weight ≥50 kg and ≤30

Exclusion criteria

Exclusion Criteria:

  • Conditions that result in the participant being unable to complete the experiment
  • Medical history with elevated intraocular pressure (e.g. glaucoma)
  • Medical history with severe heart or liver disease
  • Aneurysmal vascular disease or arteriovenous malformations
  • Medical history with severe neurological disease except of headache
  • BP measured at baseline before CH attack (Systolic> 140 mmHg or / and diastolic blood pressure> 90 mm Hg)
  • Medical history with severe depression or psychosis
  • A previous history of drug abuse
  • Consumption of illegal drugs within the last 6 months
  • Medical history of nasal abnormality or dysfunction (e.g. rhinitis)
  • High disposition for larynges or apnea
  • Positive pregnancy test before treatment and breastfeeding
  • Known to ketamine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Interventions

  • One Cluster headache attack is treated with intranasal ketamine

06

What researchers measure

Primary outcomes

  1. Effect on pain intensity at 15 min (50% reduction)

    A 50% or more reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable pain) at T15 from pain intensity at T=0 .

    Time frame: 15 minutes

Secondary outcomes

  1. Effect on pain intensity at 30 min

    A 50% or more reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable pain) at T30 from pain intensity at T=0.

    Time frame: 30 minutes

  2. Effect on pain intensity at 15 min (25% reduction)

    A 25% reduction in pain on a ten-point NRS scale (0: no pain, 10: worst imaginable in) at T15 from pain intensity at T=0.

    Time frame: 15 minutes

  3. Proportion of patients achieving NRS less than 4 at 15 minutes

    Proportion of patients achieving NRS less than 4 at 15 minutes

    Time frame: 15 minutes

  4. Proportion of patients achieving NRS less than 4 at 30 minutes

    Proportion of patients achieving NRS less than 4 at 30 minutes

    Time frame: 30 minutes

  5. Proportion of patients receiving rescue medication at 15 minutes

    Proportion of patients receiving rescue medication at 15 minutes

    Time frame: 15 minutes

  6. Proportion of patients preferring ketamine treatment compared to oxygen or injectable sumatriptan.

    Proportion of patients preferring ketamine treatment compared to oxygen or injectable sumatriptan.

    Time frame: 180 minutes (entire attack)

  7. Proportion of patients experiencing serious side effects during treatment

    Proportion of patients experiencing serious side effects during treatment

    Time frame: one week follow-up.

07

Study locations

1 site
  • Danish Headache Center
    Glostrup, DK-2600, Denmark
08

References and documents

Individual participant data

Plan to share: No — Do to GDPR rules individual data will not be shared. Group data will be presented in publication. By request by other researcher other data will be presented if the request lines within the out approval from the The Danish Data Protection Agency

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in May 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 27, 2019
StartActual
Nov 20, 2019
Primary completionActual
May 12, 2020
CompletionActual
May 25, 2020
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04179266
Lead sponsor
CCH Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Nov 20, 2019
Primary completion
May 12, 2020
Completion
May 25, 2020
Last update
Feb 24, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion